The Current Ratio as of September 2024 (TTM) for Orgenesis Inc. (ORGS) is 0.07

According to Orgenesis Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 0.07. This represents a change of -70.48% compared to the average of 0.25 of the last 4 quarters.

Orgenesis Inc. (ORGS) Historical Current Ratio (quarterly & annually)

How has ORGS Current Ratio performed in the past?

The mean historical Current Ratio of Orgenesis Inc. over the last ten years is 1.22. The current 0.07 Current Ratio has changed 507.28% with respect to the historical average. Over the past ten years (40 quarters), ORGS's Current Ratio was at its highest in in the September 2020 quarter at 7.69. The Current Ratio was at its lowest in in the March 2024 quarter at 0.07.

Orgenesis Inc. (ORGS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Orgenesis Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Orgenesis Inc. (ORGS) Average Current Ratio

How has ORGS Current Ratio performed in the past?

The current Current Ratio of Orgenesis Inc. (ORGS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Orgenesis Inc. (ORGS) Current Ratio vs. Peers

How is ORGS’s Current Ratio compared to its peers?

Orgenesis Inc.’s Current Ratio is less than TFF Pharmaceuticals, Inc. (1.63), less than Oncorus, Inc. (1.50), less than Quoin Pharmaceuticals, Ltd. (3.35), less than Apexigen, Inc. (0.82), less than Aerovate Therapeutics, Inc. (6.51), less than Adagene Inc. (2.50), less than Acrivon Therapeutics, Inc. Common Stock (16.16), less than Rezolute, Inc. (11.82), less than AN2 Therapeutics, Inc. (10.61), less than NeuroBo Pharmaceuticals, Inc. (0), less than Indaptus Therapeutics, Inc. (2.94), less than Pasithea Therapeutics Corp. (3.88), less than Lixte Biotechnology Holdings, Inc. (6.20), less than Eliem Therapeutics, Inc. (6.33), less than Design Therapeutics, Inc. (60.41), less than Tango Therapeutics, Inc. (41.42), less than Talaris Therapeutics, Inc. (7.49), less than Achilles Therapeutics plc (18.64), less than null (8.24),

Build a custom stock screener for Orgenesis Inc. (ORGS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Orgenesis Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Orgenesis Inc. (ORGS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Orgenesis Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.